October 16, 2006 — The European Commission has approved pregabalin capsules for the treatment of central neuropathic pain associated with spinal cord injury, stroke, and multiple sclerosis; and ...

Phase 3 data show treatment with REMICADE® (infliximab) resulted in rapid, significant improvement and long-term response in patients with moderate to severe plaque psoriasis. Findings from the ...

May 15, 2006 — Health Canada has approved a 500-mg tablet formulation of saquinavir mesylate that significantly reduces the daily pill count for patients with HIV; the European Commission has approved ...

ATLANTA, Nov. 8, 2010 /PRNewswire/ -- Patients with active moderate to severe rheumatoid arthritis (RA) inadequately responding to either etanercept (Enbrel ®) or adalimumab (Humira ®) and who were ...

ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...

NEW YORK (Reuters) - Crohn's disease patients taking Johnson & Johnson's Remicade either alone or with azathioprine experienced steroid-free remission in significantly greater numbers than those ...

Hidradenitis suppurativa (HS) is a difficult-to-treat skin condition that has responded to infliximab, although payer support in this setting is often lacking. Investigators have reported equivalent ...

LOS ANGELES, Dec 21 (Reuters) - Johnson & Johnson and Schering-Plough Corp said on Friday their distribution agreement for rheumatoid arthritis treatment Remicade and golimumab, J&J's next-generation ...

TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...